You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
|
|---|---|
| Published in |
BMC Pharmacology and Toxicology, April 2015
|
| DOI | 10.1186/s40360-015-0007-z |
| Pubmed ID | |
| Authors |
M Elle Saine, Dena M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re |
| Abstract |
The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD(SM)) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRD(SM): 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRD(SM): 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. ClinicalTrials.gov identifiers NCT01086280 , NCT01086293 , NCT01086319 , NCT01086306 , and NCT01377935. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| United Kingdom | 2 | 40% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 40% |
| Practitioners (doctors, other healthcare professionals) | 2 | 40% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 16% |
| Researcher | 9 | 15% |
| Other | 7 | 11% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Doctoral Student | 4 | 6% |
| Other | 9 | 15% |
| Unknown | 17 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 15% |
| Nursing and Health Professions | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Computer Science | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 21 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2016.
All research outputs
#13,378,172
of 23,576,969 outputs
Outputs from BMC Pharmacology and Toxicology
#170
of 452 outputs
Outputs of similar age
#122,525
of 264,585 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#8
of 9 outputs
Altmetric has tracked 23,576,969 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 452 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,585 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.